Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide

Enrollment ongoing in the Phase 1 monotherapy study of NUV-868

Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023

Announced formation of oncology-focused Scientific Advisory Board

Strong balance sheet with cash, cash equivalents and marketable securities of $630.9 million as of June 30, 2023

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2023, and provided a business update.

"We continue to enroll patients in the Phase 1 and Phase 1b studies of NUV-868 where dose escalation is ongoing. We also look forward to expanding our pipeline as we progress our first nominated DDC clinical candidate toward an IND filing, which we expect by the end of 2023,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "Lastly, we announced the formation of our Scientific Advisory Board, composed of leading experts in oncology drug and clinical development. We are excited to work alongside them to bring innovative new therapies to cancer patients.”

Recent Business Updates

NUV-868, BD2-Selective BETi: Advanced solid tumors

  • Dosing underway in both regimens of the Phase 1b combination study. Nuvation Bio continues to enroll the Phase 1b study of NUV-868 in combination with olaparib in patients with ovarian cancer, pancreatic cancer, metastatic castration-resistant prostate cancer (mCRPC), triple negative breast cancer and other solid tumors, and in combination with enzalutamide in patients with mCRPC.
  • Dosing underway in the Phase 1 monotherapy study. Nuvation Bio continues to enroll the Phase 1 monotherapy study in advanced solid tumors.

Drug-Drug Conjugate Platform: Solid tumors

  • Nominated first clinical candidate. Nuvation Bio remains on track to submit an Investigational New Drug (IND) application for an undisclosed DDC candidate with the U.S. Food and Drug Administration by year end 2023.

Corporate Updates

  • Announced formation of oncology-focused Scientific Advisory Board. The Scientific Advisory Board will work alongside the Nuvation Bio management team to advance its pipeline of therapeutic candidates for some of the most difficult-to-treat cancers.

Second Quarter 2023 Financial Results

As of June 30, 2023, Nuvation Bio had cash, cash equivalents and marketable securities of $630.9 million. For the three months ended June 30, 2023, research and development expenses were $18.6 million, compared to $28.9 million for the three months ended June 30, 2022. The decrease was primarily due to a $0.7 million decrease in personnel-related costs driven by a headcount reduction as well as a $9.6 million decrease in third-party costs related to research services and manufacturing primarily due to the termination of the NUV-422 program.

For the three months ended June 30, 2023, general and administrative expenses were $7.5 million, compared to $8.9 million for the three months ended June 30, 2022. The decrease was primarily due to a $0.6 million decrease in insurance, a $0.6 million decrease in recruiting and computer expenses, a $0.6 million decrease in legal fees and a $0.2 million decrease in other professional fees offset by a $0.6 million increase in personnel-related costs driven by stock-based compensation and other benefits.

For the three months ended June 30, 2023, Nuvation Bio reported a net loss of $20.6 million, or $(0.09) per share. This compares to a net loss of $34.9 million, or $(0.16) per share, for the comparable period in 2022.

About Nuvation Bio

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potential therapeutic benefit of Nuvation Bio’s product candidates, the expected continued momentum of Nuvation Bio’s clinical trials and the expected timing of an IND filing for Nuvation Bio’s first DDC clinical candidate. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q to be filed with the SEC on August 3, 2023, under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

NUVATION BIO INC. and Subsidiaries
Consolidated Balance Sheets
Unaudited
(In thousands, except share and per share data)

June 30,

 

 December 31,

2023

 

2022

 
Assets
Current assets:
Cash and cash equivalents

$

50,065

 

$

101,099

 

Prepaid expenses and other current assets

 

3,531

 

 

3,819

 

Marketable securities

 

580,835

 

 

559,915

 

Interest receivable on marketable securities

 

2,795

 

 

2,485

 

Total current assets

 

637,226

 

 

667,318

 

Property and equipment, net

 

804

 

 

894

 

Operating lease right-of-use assets

 

3,242

 

 

3,791

 

Lease security deposit

 

138

 

 

138

 

Total assets

$

641,410

 

$

672,141

 

 
Liabilities and stockholders' equity
Current liabilities:
Accounts payable

$

2,577

 

$

2,139

 

Current operating lease liabilities

 

1,283

 

 

1,206

 

Accrued expenses

 

9,553

 

 

9,816

 

Total current liabilities

 

13,413

 

 

13,161

 

Warrant liability

 

972

 

 

850

 

Non-current operating lease liabilities

 

2,393

 

 

3,054

 

Total liabilities

 

16,778

 

 

17,065

 

 
Stockholders' equity
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000
(Class A 1,000,000,000, Class B 60,000,000) shares authorized as of June 30, 2023 and December 31, 2022,
218,899,462 (Class A 217,899,462, Class B 1,000,000) and 218,632,699 (Class A 217,632,699, Class B 1,000,000)
shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively

 

938,395

 

 

927,604

 

Accumulated deficit

 

(309,368

)

 

(267,002

)

Accumulated other comprehensive income

 

(4,395

)

 

(5,526

)

Total stockholders' equity

 

624,632

 

 

655,076

 

Total liabilities and stockholders' equity

$

641,410

 

$

672,141

 

NUVATION BIO INC. and Subsidiaries
 
Consolidated Statements of Operations and Comprehensive Loss  
(In thousands, except per share data)

Three Months Ended June 30,

 

 Six Months Ended June 30,

2023

 

2022

 

2023

 

2022

 
Operating expenses:
Research and development

$

18,590

 

$

28,922

 

$

37,377

 

$

49,650

 

General and administrative

 

7,541

 

 

8,948

 

 

15,275

 

 

16,411

 

Total operating expenses

 

26,131

 

 

37,870

 

 

52,652

 

 

66,061

 

 
Loss from operations

 

(26,131

)

 

(37,870

)

 

(52,652

)

 

(66,061

)

 
Other income (expense):
Interest income

 

6,086

 

 

841

 

 

11,065

 

 

1,798

 

Investment advisory fees

 

(231

)

 

(215

)

 

(461

)

 

(384

)

Change in fair value of warrant liability

 

(265

)

 

3,080

 

 

(123

)

 

9,404

 

Realized loss on marketable securities

 

(99

)

 

(694

)

 

(195

)

 

(908

)

Total other income (expense), net

 

5,491

 

 

3,012

 

 

10,286

 

 

9,910

 

 
Loss before income taxes

 

(20,640

)

 

(34,858

)

 

(42,366

)

 

(56,151

)

 
Provision for income taxes

 

-

 

 

-

 

 

-

 

 

-

 

 
Net loss

$

(20,640

)

$

(34,858

)

$

(42,366

)

$

(56,151

)

Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic and diluted

$

(0.09

)

$

(0.16

)

$

(0.19

)

$

(0.26

)

Weighted average common shares outstanding, basic and diluted

 

218,848

 

 

216,603

 

 

218,795

 

 

215,016

 

 
Comprehensive loss:
Net loss

$

(20,640

)

$

(34,858

)

$

(42,366

)

$

(56,151

)

Other comprehensive loss, net of taxes:
Unrealized (loss) gain on available-for-sale securities

 

(1,457

)

 

(761

)

 

1,131

 

 

(5,793

)

 
Comprehensive loss

$

(22,097

)

$

(35,619

)

$

(41,235

)

$

(61,944

)

 

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.